BACKGROUND
In hereditary angioedema, a rare bradykinin-mediated condition, oral on-demand treatments facilitating prompt administration and providing rapid, sustained relief and attack resolution remain scant. We investigated the efficacy and safety of deucrictibant, an oral bradykinin B2 receptor antagonist, for on-de...
M. Riedl, P. Li, A. Adatia et al.· The Lancet· 1 citation
ABSTRACT Introduction Hereditary Angioedema (HAE) is a rare disease affecting approximately 1 in 50,000 people. It results in angioedema of the skin, abdominal tract and upper airway that results in disfiguration, abdominal pain and potential for asphyxia. Early therapies for HAE have significant drug burden due to int...
Van Bui, Shane Stone, Bharosha Bhattarai et al.· Expert Opinion on Pharmacoth...· 0 citations
Lonvo-z uses CRISPR/Cas9 technology to permanently reduce production of prekallikrein that triggers swelling attacks in HAE, potentially providing long-lasting disease control after a single treatment.
L. Luong, Shane Stone, Van Bui et al.· Expert Opinion on Investigat...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.